Global Bullous Pemphigoid Clinical Trials Market H2 2014 in New Research Report Available at ReportsnReports.com

Share Article

ReportsnReports.com adds “Bullous Pemphigoid Global Clinical Trials Review, H2, 2014” to its store. This report provides elemental information and data relating to the clinical trials on Bullous Pemphigoid.

Bullous Pemphigoid Clinical Trials Market

Bullous Pemphigoid Clinical Trials Market

Clinical trial report, “Bullous Pemphigoid Global Clinical Trials Review, H2, 2014" provides data on the Bullous Pemphigoid clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Bullous Pemphigoid. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Bullous Pemphigoid. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData''s team of industry experts. Complete Report Available @ http://www.reportsnreports.com/reports/314249-bullous-pemphigoid-global-clinical-trials-review-h2-2014.html .

Bullous pemphigoid is an acute or chronic autoimmune skin disease, involving the formation of blisters, more appropriately known as bullae, at the space between the skin layers epidermis and dermis. It is classified as a type II hypersensitivity reaction. Clinically, the earliest lesions may appear urticarial (like hives). Tense bullae eventually erupt, most commonly at the inner thighs and upper arms, but the trunk and extremities are frequently both involved. Any part of the skin surface can be involved. Oral lesions are present in a minority of cases. The disease may be acute, but typically will wax and wane. Several other skin diseases may have similar symptoms. However, milia are more common with epidermolysis bullosa acquisita, because of the deeper antigenic targets. A more ring-like configuration, with a central depression or centrally collapsed bullae may indicate linear IgA disease. Nikolsky's sign is negative unlike pemphigus vulgaris where it is positive.

Clinical Trial Overview of Top Companies:
Novartis AG, Dompe Farmaceutici S.p.A, Immune Pharmaceuticals, Inc..

Clinical Trial Overview of Top Institutes / Government:
Rouen University Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China Academy of Chinese Medical Sciences, Peter MacCallum Cancer Centre, University of Nottingham, University Hospital, Limoges, National Taiwan University Hospital, University Hospital Inselspital, Berne, Universitatsklinikum Munster, Duke University.

Order a Purchase copy at http://www.reportsnreports.com/Purchase.aspx?name=314249 .

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons To Buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Inquire for Discount at http://www.reportsnreports.com/contacts/Discount.aspx?name=314249 . (This is a premium report priced at US$2500 for a single user License.)

Major Points in Table of Content:

Table of Contents
List of Tables
List of Figures

Introduction
Bullous Pemphigoid
Report Guidance

Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa

Clinical Trials by G7 Countries: Proportion of Bullous Pemphigoid to Immunology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Bullous Pemphigoid to Immunology Clinical Trials

Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Unaccomplished Trials of Bullous Pemphigoid
Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors
Top Companies Participating in Bullous Pemphigoid Therapeutics Clinical Trials
Prominent Drugs

Latest Clinical Trials News on Bullous Pemphigoid
Jul 30, 2014: Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin

Clinical Trial Profiles

Clinical Trial Overview of Top Companies

Clinical Trial Overview of Top Institutes / Government

Five Key Clinical Profiles

Appendix

Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us:
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
ReportsnReports
+1 (888) 391-5441
Email >
Sandler Research
Like >
Follow us on
Visit website